Aditya Bardia, MD, MPH - Reducing Endocrine Resistance in Early Breast Cancer: Will Oral Selective Estrogen Receptor Degraders Provide New Hope?

episode

CME in Minutes: Education in Oncology & Hematology not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

7 Day Ceasefire Iran Offer, Trump-Xi AI Rivalry, More 10 min · 25 Sep 2026 · Bloomberg News Now

#685 - Joey Diaz 1h 59m · 25 Sep 2026 · This Past Weekend w/ Theo Von

NPR News: 09-25-2026 1AM EDT 5 min · 25 Sep 2026 · NPR News Now

1AM ET 09/25/2026 Newscast 3 min · 25 Sep 2026 · Fox News Hourly Update

The Same Yesterday, Today, and Forever 6 min · 25 Sep 2026 · Things Unseen with Sinclair B. Ferguson

The killer driver and member of Cock-Wall gang who poured bleach on elderly woman 22 min · 25 Sep 2026 · Crime World

Report any issue

Source

Recorded15 Nov 2022

Publisherc.answersincme.com ↗

Handlerec:766100

Show notes

Please visit answersincme.com/YZZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses estrogen receptor–positive breast cancer. Upon completion of this activity, participants should be better able to: Describe the rationale for investigating oral selective estrogen receptor degraders (SERDs) for the treatment of ER-positive early breast cancer; Review the clinical profiles of emerging oral SERDs for the treatment of patients with ER-positive early breast cancer; and Outline clinical approaches where oral SERDs may be appropriate based on their clinical profile in ER-positive early breast cancer.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in